Nanomedical Diagnostics, a biotech company that aims to create practical and scalable graphene biological field effect transistor (BioFET) products, announced the completion of its first AGILE (Automatic Graphene Immunolinked Electronic) biosensor Early Access Development Kit test with a lab at the University of Colorado Anschutz Medical Campus.
The lab needed in vitro protein concentration measurements to validate its RNA data, but doing so using traditional protein analysis methods such as Western Blot was almost impossible due to the amount of tissue required to observe the protein. The AGILE platform reportedly provided quantitative, reproducible protein concentration data in one afternoon. One of the professors from the University of Colorado Anschutz Medical Campus declared that “This technology is a game-changer for developmental biologists” and that “It opens the field of proteomics to a discipline that’s previously used just RNA data because it was cost-prohibitive to gain the quantity of protein needed for detection on traditional platforms.”
AGILE requires a significantly smaller amount of starting material than traditional methods, which also reduces sample costs. Because AGILE can sense protein in crude tissue lysates with high sensitivity, the lab was also able to avoid protein loss from multiple purification steps. AGILE is the world’s first and only commercially available graphene biosensor. It is an all-electronic, portable, label-free system that provides real-time analysis of biomolecular interactions including kinetics, affinity, and concentration. AGILE sensors are now available to participants in Nanomedical Diagnostics’ Early Access Dev Kit program.
In September 2015, Nanomedical Diagnostics launched its first product, AGILE Research.